Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 but also to the receptors for glucose-dependen...
| 主要作者: | |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2022-10-01
|
| 叢編: | Frontiers in Endocrinology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fendo.2022.1004044/full |